273 related articles for article (PubMed ID: 29318382)
21. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
Kluiver J; Haralambieva E; de Jong D; Blokzijl T; Jacobs S; Kroesen BJ; Poppema S; van den Berg A
Genes Chromosomes Cancer; 2006 Feb; 45(2):147-53. PubMed ID: 16235244
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6.
Ma J; Li T; Yuan H; Han X; Shui S; Guo D; Yan L
J Cell Biochem; 2018 Mar; 119(3):2617-2626. PubMed ID: 29023945
[TBL] [Abstract][Full Text] [Related]
23. Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.
Dong L; Huang J; Zu P; Liu J; Gao X; Du J; Li Y
Bioengineered; 2021 Dec; 12(1):7995-8005. PubMed ID: 34658308
[TBL] [Abstract][Full Text] [Related]
24. Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma.
Maugeri M; Barbagallo D; Barbagallo C; Banelli B; Di Mauro S; Purrello F; Magro G; Ragusa M; Di Pietro C; Romani M; Purrello M
Oncotarget; 2016 Dec; 7(50):83330-83341. PubMed ID: 27829219
[TBL] [Abstract][Full Text] [Related]
25. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
[TBL] [Abstract][Full Text] [Related]
26. miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma.
Zhang D; Wei Y; Zhou J; Wang G; Xiao L; Xu J; Wei N; Li W; Zhang M
J Cell Physiol; 2019 Jun; 234(6):9652-9662. PubMed ID: 30422313
[TBL] [Abstract][Full Text] [Related]
27. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
[TBL] [Abstract][Full Text] [Related]
28. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
29. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
30. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
Leucci E; Onnis A; Cocco M; De Falco G; Imperatore F; Giuseppina A; Costanzo V; Cerino G; Mannucci S; Cantisani R; Nyagol J; Mwanda W; Iriso R; Owang M; Schurfeld K; Bellan C; Lazzi S; Leoncini L
Int J Cancer; 2010 Mar; 126(6):1316-26. PubMed ID: 19530237
[TBL] [Abstract][Full Text] [Related]
31. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
[TBL] [Abstract][Full Text] [Related]
32. Circular ZDHHC11 supports Burkitt lymphoma growth independent of its miR-150 binding capacity.
Liu Y; Zhao X; Seitz A; Hooijsma AA; Ravanbakhsh R; Sheveleva S; de Jong D; Koerts J; Dzikiewicz-Krawczyk A; van den Berg A; Ziel-Swier LJYM; Kluiver J
Sci Rep; 2024 Apr; 14(1):8730. PubMed ID: 38627588
[TBL] [Abstract][Full Text] [Related]
33. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
[TBL] [Abstract][Full Text] [Related]
34. [Effects of Emodin Derivative on Cell Cycle, Apoptosis and NF-κB Pathway in Burkitt Lymphoma Cells].
Cheng DF; Yang BX; Liu WJ; Qiu CX; Liao JR; Qiu YY; Liu TB; Hu JD; Wang WF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):474-488. PubMed ID: 33812418
[TBL] [Abstract][Full Text] [Related]
35. Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro.
Chen S; Wang Z; Dai X; Pan J; Ge J; Han X; Wu Z; Zhou X; Zhao T
Cancer Sci; 2013 Jul; 104(7):826-34. PubMed ID: 23521217
[TBL] [Abstract][Full Text] [Related]
36. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
37. miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis.
Shi C; Rao C; Sun C; Yu L; Zhou X; Hua D; Wang R; Luo W; Jiang Z; Zhou J; Wang Q; Yu S
Cell Death Dis; 2018 Oct; 9(11):1078. PubMed ID: 30348972
[TBL] [Abstract][Full Text] [Related]
38. DNA Methylation Mediated Downregulation of miR-449c Controls Osteosarcoma Cell Cycle Progression by Directly Targeting Oncogene c-Myc.
Li Q; Li H; Zhao X; Wang B; Zhang L; Zhang C; Zhang F
Int J Biol Sci; 2017; 13(8):1038-1050. PubMed ID: 28924385
[TBL] [Abstract][Full Text] [Related]
39. IG-
Wagener R; López C; Kleinheinz K; Bausinger J; Aukema SM; Nagel I; Toprak UH; Seufert J; Altmüller J; Thiele H; Schneider C; Kolarova J; Park J; Hübschmann D; Murga Penas EM; Drexler HG; Attarbaschi A; Hovland R; Kjeldsen E; Kneba M; Kontny U; de Leval L; Nürnberg P; Oschlies I; Oscier D; Schlegelberger B; Stilgenbauer S; Wössmann W; Schlesner M; Burkhardt B; Klapper W; Jaffe ES; Küppers R; Siebert R
Blood; 2018 Nov; 132(21):2280-2285. PubMed ID: 30282799
[TBL] [Abstract][Full Text] [Related]
40. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
